TY - JOUR T1 - COVID-19 among patients with hepatitis B or hepatitis C: A systematic review JF - medRxiv DO - 10.1101/2020.10.22.20216317 SP - 2020.10.22.20216317 AU - Hossein Mirzaie AU - Mohammad Vahidi AU - Mostafa Shokoohi AU - Maryam Darvishian AU - Hamid Sharifi AU - Heidar Sharafi AU - Mohammad Karamouzian Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/10/23/2020.10.22.20216317.abstract N2 - Background & aims Hepatic manifestations of coronavirus disease 2019 (COVID-19) are common among people infected with hepatitis B virus (HBV) and hepatitis C virus (HCV). This systematic review aimed to summarize the evidence on COVID-19 patients with HBV or HCV co-infections.Methods We searched multiple electronic databases and preprint servers from December 1, 2019 to August 9, 2020. Studies were included if they reported quantitative empirical data on COVID-19 patients with HBV or HCV co-infections. Descriptive analyses were reported and data were narratively synthesized. Quality assessments was completed using the Joanna Briggs Institute critical appraisal tools.Results Out of the 941 identified records, 28 studies were included. Of the eligible studies, 235 patients with COVID-19 were infected with HBV and 22 patients with HCV. Most patients were male and mean age was 49.8 and 62.8 in patients with HBV and HCV, respectively. Death proportion was 6% among COVID-19-HBV and 13% among COVID-19-HCV co-infected patients. Among COVID-19 patients, 34.1% and 76.2% reported at least one comorbidity besides HBV and HCV infections, mainly hypertension and diabetes mellites type 2. The most common COVID-19-related symptoms in both HBV and HCV groups were fever, cough and dyspnea. ICU admission was reported in 14.1% and 21.4% of individuals with HBV and HCV, respectively.Conclusions Our findings suggest a considerable risk of morbidity and mortality among COVID-19 patients with HBV and HCV. Careful assessment of hepatic manifestations upon admission of patients could help improve health outcomes among COVID-19 patients with HBV or HCV co-infections.Key PointsHepatic manifestations of COVID-19 are common among people infected with HBV and HCV.Among COVID-19 patients, 34.1% and 76.2% reported at least one comorbidity besides HBV and HCV infections.The most common COVID-19-related symptoms in both HBV and HCV groups were fever, cough and dyspnea.There is a considerable risk of mortality among COVID-19 patients with HBV and HCV.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAClinical Protocols https://osf.io/p4w3j/ Funding StatementNo funding was received for this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NA; This is a systematic reviewAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is presented in the paper ER -